STM publisher Elsevier, Netherlands, has announced the acquisition of Shanghai Datong Medical Information Technology Co., Ltd., a drug decision support provider in China. Datong's products will enable Elsevier to enter the emerging clinical decision support (CDS) market in China, helping Chinese hospitals to improve their quality of care through better drug usage and reduced prescription errors.
Datong's flagship product 'Clinical Drug Consultation and Safety Monitoring System' is embedded in the hospital's computerised physician order system and provides drug based alerts and warnings at order entry as well as drug reference information. Launched in early 2002, the product is used by hospitals in 123 cities across 29 provinces, autonomous regions and municipal cities in China. Datong's new products 'Utilization Analysis and Controls System for Anti-Bacteria Agents' and 'Prescription Review and Evaluation Program' are unique tools which help hospitals comply with new drug usage safety regulations.
After the acquisition, Elsevier will integrate its global advanced CDS content and technology with Datong's locally-tailored products and services to help Chinese hospitals and pharmacies to achieve reform objectives.
Financial details of the acquisition are not being disclosed.
Search for more Decision Support Tools
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
